Geron (GERN) Set to Release Quarterly Earnings on Wednesday

Geron (NASDAQ:GERN) is projected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Geron to announce earnings of ($0.01) per share and revenue of $60.35 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The business had revenue of $57.48 million for the quarter, compared to the consensus estimate of $55.30 million. On average, analysts expect Geron to post ($0.05) EPS for the current fiscal year and $0.06 EPS for the next fiscal year.

Geron Stock Performance

Shares of GERN opened at $1.15 on Wednesday. The firm’s 50-day moving average is $1.33 and its two-hundred day moving average is $1.43. Geron has a twelve month low of $1.04 and a twelve month high of $2.01.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.00.

About Geron

Geron Corporation (NASDAQ: GERN) is a biopharmaceutical company focused on developing and commercializing treatments for blood cancers and other serious hematologic diseases. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor designed to target malignant blood-forming cells.

Rytelo is approved in the United States for adults with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia requiring regular red blood cell transfusions and have not responded adequately to, or are not eligible for, erythropoiesis-stimulating agents.